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Metabolic syndrome (MetS) doubles the risk of adverse
cardiovascular events. Glucagon-like peptide 1 (GLP-1)
receptor agonists induce weight loss, increase insulin
secretion, and improve glucose tolerance. Studies in
healthy animals suggest cardioprotective properties of
GLP-1 receptor agonists, perhaps partially mediated by
improved sarco-endoplasmic reticulum Ca2+ ATPase
(SERCA) activity. We examined the acute effect of
GLP-1 receptor agonists on coronary smooth muscle
cells (CSM) enzymatically isolated from lean, healthy
Ossabaw miniature swine. Intracellular Ca2+ handling
was interrogated with fura-2. The GLP-1 receptor ago-
nist exenatide activated SERCA but did not alter other
Ca2+ transporters. Further, we tested the hypothesis
that chronic, in vivo treatment with GLP-1 receptor ag-
onist AC3174 would attenuate coronary artery disease
(CAD) in swine with MetS. MetS was induced in 20 swine
by 6 months’ feeding of a hypercaloric, atherogenic diet.
Swine were then randomized (n = 10/group) into placebo
or AC3174 treatment groups and continued the diet for
an additional 6 months. AC3174 treatment attenuated
weight gain, increased insulin secretion, and improved
glucose tolerance. Intravascular ultrasound and histol-
ogy showed no effect of AC3174 on CAD. MetS abol-
ished SERCA activation by GLP-1 receptor agonists.
We conclude that MetS confers vascular resistance to
GLP-1 receptor agonists, partially through impaired cel-
lular signaling steps involving SERCA.
Metabolic syndrome (MetS) is deﬁned as the presence of
three or more of the following ﬁve risk factors: obesity,
hypertension, glucose intolerance, insulin resistance, and
dyslipidemia (1). Obesity, MetS, and type 2 diabetes are
all independent risk factors for cardiovascular disease.
The presence of MetS doubles the risk of experiencing
an adverse cardiovascular event (2). Thus, it is important
to understand the effect of diabetes and MetS treatment
modalities on cardiovascular health.
Insulin-sensitizing drugs and those that enhance insulin
secretion from pancreatic b-cells have been used in the treat-
ment of type 2 diabetes and MetS. Others, such as dipeptidyl
peptidase-4 inhibitors and glucagon-like peptide 1 (GLP-1) re-
ceptor agonists (exenatide, liraglutide, AC3174, etc.), increase
both insulin sensitivity and insulin secretion (3,4). Recently,
insulin-sensitizing thiazolidinediones have been implicated in
increased risk of ﬂuid retention, LDL and triglyceride accumu-
lation, heart failure, and myocardial infarction (5–7). Hence,
there is great attention on cardiovascular outcomes of antidi-
abetic agents, and the U.S. Food and Drug Administration
requires cardiovascular safety proﬁles for all new agents (8).
GLP-1 receptor agonists are attractive treatment options
for MetS because GLP-1 is an endogenous hormone that
functions in normal physiology to increase insulin sensitiv-
ity, biosynthesis, and secretion (3). Additionally, GLP-1 re-
ceptor agonists reduce myocardial infarct size in ischemia/
reperfusion injury (9), improve cardiac function in chronic
heart failure (10), and attenuate neointimal formation after
vascular injury (11). At the cellular level, GLP-1 receptor
agonists improve endothelial calcium homeostasis after
simulated ischemia/reperfusion (12). Further, GLP-1 recep-
tor agonists improve sarco-endoplasmic reticulum Ca2+ ATPase
(SERCA) activity in multiple cell types (13,14). These
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studies provide rationale for a protective role of GLP-1
in the coronary vasculature.
A recent study revealed impaired GLP-1 stimulation of
myocardial glucose uptake in human patients with type 2
diabetes and in MetS swine (15). This ﬁnding raises the
question of potential resistance to GLP-1 in MetS and type 2
diabetes and highlights the need for rigorous examination
of GLP-1 action on coronary artery disease (CAD), speciﬁ-
cally in MetS. Given the stimulation of SERCA in macro-
phages and ventricular myocytes (13,14) and altered SERCA
in coronary smooth muscle cells (CSM) in MetS and diabetes
(16,17), potentially vasoprotective actions of GLP-1 could be
mediated through cellular Ca2+ signaling. This study inves-
tigated the effect of GLP-1 receptor agonists on SERCA
stimulation in CSM from lean swine and on CAD and
CSM SERCA stimulation in MetS.
RESEARCH DESIGN AND METHODS
Animals
All protocols involving animals were approved by the
Institutional Animal Care and Use Committee at Indiana
University School of Medicine and fully complied with
animal use standards (18,19). Ossabaw miniature swine
were separated into two treatment groups: placebo (n =
10) and GLP-1 receptor agonist AC3174 treated (n = 10;
0.25 mg/kg body weight subcutaneously, twice daily; Amy-
lin Pharmaceuticals, San Diego, CA), which displays nearly
identical pharmacokinetic and pharmacodynamics proﬁles
as the marketed GLP-1 receptor agonist exenatide (4). CAD
and MetS were induced in both treatment groups as de-
scribed in the Supplementary Material. One animal in the
placebo group died prior to the collection of end point data.
Isolation of CSM
Epicardial coronary arteries were cleaned of adherent
tissue and CSM were isolated with a collagenase solution
as previously described (16,17).
Measurement of Intracellular Ca2+
CSM were loaded with fura-2/AM, and whole-cell in-
tracellular Ca2+ levels were measured as described in the
Supplementary Material.
Acute In Vitro Exenatide Treatment
CSM from lean, healthy Ossabaw swine or a separate group
of swine with MetS and CAD were treated with 100 nmol/L
exenatide during assessment of intracellular Ca2+. The se-
lective SERCA inhibitor cyclopiazonic acid (CPA; 10 mmol/L)
was used as a negative control for SERCA function.
Intravenous Glucose Tolerance Testing
Intravenous glucose tolerance testing (IVGTT) was per-
formed as previously described (16,20) and in the Supple-
mentary Material.
Plasma Lipid, Electrolyte, and Enzyme Assays
Blood samples were obtained at time of IVGTT prior to
intravenous injection of glucose. Lipid electrolyte and
enzyme content were measured offsite (Antech Diagnos-
tics, West Lafayette, IN).
Intravascular Ultrasound
After 12 months on the diet, intravascular ultrasound (IVUS)
pullbacks were performed as described in the Supplemen-
tary Material.
Histology
Coronary arterial rings were placed in phosphate-buffered
formalin at the time of euthanasia. Hematoxylin and eosin,
Verhoeff-van Gieson, and trichrome staining were per-
formed on sections of these rings. Plaque burden and
collagen content were determined using commercially
available software (ImageJ 1.48v; National Institutes of
Health) as previously described (16).
RESULTS
Acute In Vitro Exenatide Treatment in CSM From Lean,
Healthy Swine
We investigated the acute effect of the GLP-1 receptor
agonist, exenatide, on intracellular Ca2+ handling in CSM
isolated from lean, healthy Ossabaw swine. Sarcoplasmic
reticulum (SR) Ca2+ stores were released with caffeine in
the absence of extracellular Ca2+ in the presence and ab-
sence of 100 nmol/L exenatide (Fig. 1A), and the subse-
quent undershoot of cytosolic Ca2+ during recovery was
assessed. Exenatide treatment did not alter resting cyto-
solic Ca2+ (Fig. 1B) or Ca2+ inﬂux through voltage-gated
Ca2+ channels (Fig. 1C). Exenatide elicited improved re-
covery of cytosolic Ca2+ below baseline levels, and this
effect was completely ablated in the presence of the
SERCA inhibitor CPA (Fig. 1D). The GLP-1 receptor ago-
nist liraglutide also demonstrated improved recovery of
cytosolic Ca2+, which was prevented by the GLP-1 receptor
antagonist, exendin (9-39) (Supplementary Fig. 1). In the
presence of caffeine, SERCA buffering of cytosolic Ca2+ is
functionally inhibited because of the much more rapid
release of Ca2+ through ryanodine receptors on the SR
membrane. Therefore, we assessed the rate of recovery
to 50% recovery to baseline (t50) in the presence of
caffeine as a measure of Ca2+ extrusion and/or Ca2+ uptake
into caffeine-insensitive intracellular stores, and to 100%
recovery to baseline (t100) in the absence of caffeine as
another measure of SERCA activation. Exenatide signiﬁ-
cantly decreased time to 100%, but not 50%, recovery to
baseline (Fig. 1E).
Clinical Measurement of MetS in Ossabaw Swine
We then investigated the chronic effect of GLP-1 receptor
agonism in vivo. To examine the effects of diet and GLP-1
receptor treatment on glucose metabolism, kidney func-
tion, and plasma electrolytes, blood proﬁles of these
parameters were obtained (Supplementary Table 1) and
IVGTTs were performed. Overall, feeding of an excess-
calorie, atherogenic diet increased body weight, which
was signiﬁcantly attenuated by AC3174 treatment (Fig.
2A). Blood pressure was not altered by diet or AC3174
treatment. Whereas fasting plasma glucose was not
altered by diet or AC3174 treatment (Supplementary
Table 1), IVGTT assessment of glucoregulation revealed
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improved glucose handling in AC3174-treated swine,
compared with placebo (Fig. 2B–D). This was corrobo-
rated by augmented plasma insulin levels after intrave-
nous glucose challenge in AC3174-treated animals,
compared with placebo (Fig. 2E–G).
Intravascular Ultrasound and Histology Measurement
of CAD
IVUS was used to examine severity of CAD in vivo and was
conﬁrmed by histology. Both wall coverage and percent
plaque burden were assessed as previously described (16) in
placebo and AC3174-treated pigs. AC3174 treatment did
not alter CAD severity, as indicated by either wall coverage
or percent plaque burden (Fig. 3C and D). In vitro, histo-
logical examination of coronary arterial rings revealed no
effect of AC3174 treatment on plaque burden (Fig. 3E, F, I,
J, and H) or collagen deposition (Fig. 3G, K, and L).
Effect of Chronic, In Vivo GLP-1 Receptor Agonist
Treatment on CSM Ca2+ Handling in MetS-Induced
CAD
We have previously demonstrated alterations in CSM Ca2+
handling in MetS-induced CAD (16,17,21). We therefore
investigated whether chronic, in vivo AC3174 treatment
resulted in improved intracellular Ca2+ handling in CSM.
Figure 4A shows the Ca2+ signaling protocol to assess
baseline Ca2+ levels, SR Ca2+ store release assessed by
the caffeine-induced Ca2+ peak in the absence of extracel-
lular Ca2+, and SERCA activity assessed by subsequent
recovery of cytosolic Ca2+ levels and undershoot of cyto-
solic [Ca2+] below baseline levels. Chronic AC3174 treat-
ment did not alter intracellular Ca2+ handling in CSM
from swine with MetS-induced CAD (Fig. 4B–D).
Effect of Acute, In Vitro Exenatide Treatment on CSM
in MetS and CAD
Further, we assessed the acute, direct effect of GLP-1
receptor agonists on Ca2+ handling in CSM isolated from
swine with MetS and CAD. Cells were exposed to the
GLP-1 receptor agonist exenatide (100 nmol/L), which
has an identical pharmacological proﬁle as AC3174 (4)
(Fig. 4A), for 3 min prior to treatment with high K+.
We again assessed caffeine-induced SR Ca2+ store release
by peak Ca2+ response to caffeine and SERCA activity by
the subsequent undershoot of cytosolic Ca2+ during
recovery. Exenatide did not alter either SR Ca2+ store
release or the undershoot of cytosolic Ca2+ below base-
line (Fig. 4E and F).
DISCUSSION
The principle ﬁnding of this study is that MetS confers
vascular resistance to the effects of GLP-1 receptor
agonists. AC3174 did improve several cardiovascular risk
factors, such as the metabolic factors, glucose tolerance,
and insulin secretion, indicating that longer-term treat-
ment may have indirect beneﬁts on cardiovascular health.
Treatment of MetS and type 2 diabetes is confounded by
potential secondary and detrimental cardiovascular
effects. Previous studies in lean, healthy animals indicate
that GLP-1 receptor agonists provide a potential cardio-
protective treatment for type 2 diabetes and MetS (9–11).
In the current study, we examined possible Ca2+ regula-
tory mechanisms for GLP-1 receptor agonist action in
CSM from lean, healthy Ossabaw swine. Our ﬁnding
that GLP-1 receptor agonists exert a positive effect on
SERCA activity in CSM from lean Ossabaw swine is in
agreement with ﬁndings that GLP-1 receptor agonists en-
hance SERCA activity in other cell types, including endo-
thelial cells (12), macrophages (13), and cardiomyocytes
(14), and is the ﬁrst study examining the effect of GLP-1
receptor agonists in CSM. The kinetics of the Ca2+ tran-
sient shown in Fig. 1E demonstrate a lack of exenatide
effect on Ca2+ extrusion. We have previously shown these
kinetic measurements to be an appropriate assay of Ca2+
extrusion (17). Reduced SERCA activity has been impli-
cated in CSM proliferation and neointimal formation in
Figure 1—Effect of acute exenatide treatment on CSM Ca2+ han-
dling in CSM isolated from lean, healthy Ossabaw swine. A: Rep-
resentative tracing of data from Ca2+ imaging protocol. Horizontal
dashed line indicates baseline. (CAF, caffeine; control, n = 114
CSM; exenatide [Exen], n = 82 CSM; CPA, n = 68 CSM.) B: Resting
cytosolic Ca2+. C: Area under the curve (AUC) for Ca2+ inﬂux during
high K+, corresponding to the shaded region in panel A. D: Under-
shoot of Ca2+ below resting levels, corresponding to the black ver-
tical arrow in panel A. E: Time to half (t50) and total (t100) recovery
from caffeine-induced rise in cytosolic Ca2+, corresponding to the
horizontal black arrows in panel A. *, different from other treat-
ments. P < 0.001.
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the progression of CAD (22,23). One possible mechanism
explaining this phenomenon is induction of endoplasmic
reticulum (ER) stress. As the single means by which Ca2+
may enter the ER, SERCA is a crucial regulator of ER Ca2+
homeostasis, and SERCA inhibition elicits an ER
stress response through depletion of ER Ca2+ (24). ER
stress is associated with the development of atheroscle-
rosis (13). Inhibition of ER stress through heightened
Figure 2—AC3174 attenuates weight gain and improves glucose handling in Ossabaw miniature swine. Closed circles, placebo treatment
group; open circles, AC3174 treatment group. A: Weight gain in Ossabaw miniature swine. Inset timeline indicates time on placebo or
AC3174 treatment, which corresponds with times in B–D and Supplementary Table 1. Time course of plasma glucose responses during
IVGTT at beginning (B), 12 weeks (C ), and 24 weeks (D) of AC3174 treatment. Time course of plasma insulin responses during IVGTT at
beginning (E), 12 weeks (F ), and 24 weeks (G) of AC3174 treatment. *, different from placebo. P < 0.05.
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activation of SERCA could provide a novel means by
which to treat CAD.
We also examined the effect of GLP-1 receptor agonists
on CAD progression in MetS. This study was needed
because of recent evidence of MetS-induced resistance to
the cardioprotective effects of GLP-1 (15). The improve-
ment of systemic glucoregulation with AC3174 treatment
provides essential positive evidence for GLP-1 receptor
agonist action in the Ossabaw swine model of MetS and
CAD. Further, we demonstrated that GLP-1 receptor ag-
onist AC3174 has no effect on MetS-induced CAD. This is
in contrast with the recent ﬁnding that GLP-1 prevents
myocardial ischemia–reperfusion injury (9) and injury-
induced neointimal hyperplasia (11), providing evidence
that the MetS phenotype itself confers cardiovascular
resistance to the beneﬁcial effects of GLP-1. It is impor-
tant to note that although AC3174 treatment did not
attenuate CAD progression, the absence of adverse
effects of AC3174 provide a cardiovascular safety proﬁle
for GLP-1 receptor agonists.
Additionally, we examined the acute, direct effect of
GLP-1 receptor agonists on intracellular Ca2+ regulation in
CSM from Ossabaw swine with MetS and CAD who had
not received any treatment with GLP-1 receptor agonists.
Here, we found that exenatide had no effect on Ca2+ reg-
ulation in CSM from swine with MetS and CAD. This ﬁnd-
ing is in contrast with other studies in which GLP-1
receptor agonism resulted in increased SERCA activity
(12–14). A study in humans with type 2 diabetes revealed
that exenatide treatment enhanced endothelial-dependent
Figure 3—AC3174 treatment does not attenuate CAD progression as measured by IVUS and histology. A: IVUS image of artery with CAD.
C, catheter; L, lumen. Distance between dots is 1 mm. Original lumen traced in white dashed line. Actual lumen traced in white dotted line.
Atherosclerotic plaque is indicated between dotted and dashed lines. B: The heart and major epicardial coronary arteries. CFX, circumﬂex; LAD,
left anterior descending; RCA, right coronary artery. The RCA and CFX on the anterior aspect of the heart are shown by the solid lines and the
arteries traversing to the posterior aspect of the heart are shown by the dashed lines. The IVUS catheter is shown in the RCA positioned for
a pullback. C and D: Quantiﬁcation of IVUS pullbacks performed in the RCA in both placebo (n = 6) and AC3174-treated (n = 3) swine. AC3174
did not attenuate CAD as measured by percent plaque burden (C) or percent wall coverage (D). Coronary arterial rings from placebo (n = 4; E–G)
and AC3174-treated (n = 5; I–K) swine. A, adventitia; I, intima; L, lumen; M, media. A and E: Coronary artery rings stained with hematoxylin and
eosin (H&E). F and J: Coronary artery rings stained with Verhoeff-van Gieson (VVG) stain for elastin. An overt atherosclerotic plaque is traced
in panel H. G and K: Coronary artery rings stained with Masson’s trichrome (TC) for collagen. H: Graphical representation of plaque burden
(P = 0.35). L: Graphical representation of total collagen area (P = 0.79).
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vasodilation (25), although it is important to note that
blood cholesterol levels were controlled in these patients.
The current study, revealing a lack of effect of GLP-1 re-
ceptor agonism on SERCA activity in the setting of MetS,
corroborates the earlier ﬁnding that MetS ablated the ef-
fect of GLP-1 receptor agonists in myocardium and high-
lights the need for additional studies to investigate speciﬁc
aspects of MetS (obesity, hyperinsulinemia, glucose intol-
erance, hypertension, and dyslipidemia) that may underlie
resistance of the coronary vasculature to GLP-1 receptor
agonists.
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